Inhibikase Therapeutics, Inc. financial data

Symbol
IKT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
3350 Riverwood Parkway Se, Suite 1900, Atlanta, Georgia
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 491 %
Debt-to-equity 26 % +78.6%
Return On Equity -147 % -107%
Return On Assets -117 % -88.7%
Operating Margin -10.3 K % +19.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.48 M shares -77.6%
Common Stock, Shares, Outstanding 6.48 M shares -79.1%
Entity Public Float 19.1 M USD +2.14%
Common Stock, Value, Issued 6.48 K USD -79.1%
Weighted Average Number of Shares Outstanding, Basic 6.34 M shares +38.3%
Weighted Average Number of Shares Outstanding, Diluted 6.34 M shares +38.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 196 K USD +38.1%
Research and Development Expense 13.5 M USD +13.8%
Costs and Expenses 20.4 M USD +10.9%
Operating Income (Loss) -20.2 M USD -10.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -19.2 M USD -7.32%
Earnings Per Share, Basic -3.32 USD/shares +34.6%
Earnings Per Share, Diluted -3.32 USD/shares +34.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.17 M USD +27.5%
Marketable Securities, Current 7.4 M USD -66%
Assets, Current 10.8 M USD -60.9%
Property, Plant and Equipment, Net 66.8 K USD -71.1%
Operating Lease, Right-of-Use Asset 193 K USD -36.2%
Assets 11.1 M USD -60.7%
Accounts Payable, Current 1.29 M USD +34.9%
Accrued Liabilities, Current 2.51 M USD +60.9%
Liabilities, Current 4.23 M USD +58.9%
Operating Lease, Liability, Noncurrent 58.3 K USD -67.3%
Liabilities 4.29 M USD +51%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.8 K USD -101%
Retained Earnings (Accumulated Deficit) -71.6 M USD -36.7%
Stockholders' Equity Attributable to Parent 6.78 M USD -73.2%
Liabilities and Equity 11.1 M USD -60.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.87 M USD +35.2%
Net Cash Provided by (Used in) Financing Activities 367 K USD -95.7%
Net Cash Provided by (Used in) Investing Activities -3.31 M USD +43.3%
Common Stock, Shares Authorized 100 M shares 0%
Common Stock, Shares, Issued 6.48 M shares -79.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.35 M USD -40.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 18.8 M USD +51.5%
Deferred Tax Assets, Gross 18.8 M USD +51.5%
Operating Lease, Liability 209 K USD -35.5%
Depreciation 179 K USD +1421%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -4.59 M USD -2.82%
Property, Plant and Equipment, Gross 104 K USD -57.3%
Operating Lease, Liability, Current 151 K USD +2.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 18.3 K USD -63.1%
Deferred Tax Assets, Operating Loss Carryforwards 9.18 M USD +33.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD -100%
Share-based Payment Arrangement, Expense 430 K USD -6.09%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%